, and the 36-month beta value for LXRX is at 1.27. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The average price suggested by analysts for LXRX is $6.33, which is $3.43 above the current market price. The public float for LXRX is 186.84M, and currently, shorts hold a 3.45% of that float. The average trading volume for LXRX on May 26, 2023 was 785.70K shares.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
LXRX) stock’s latest price update
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX)’s stock price has plunge by -3.97relation to previous closing price of 3.02. Nevertheless, the company has seen a 0.35% surge in its stock price over the last five trading sessions.
LXRX’s Market Performance
Lexicon Pharmaceuticals Inc. (LXRX) has seen a 0.35% rise in stock performance for the week, with a 20.33% gain in the past month and a 30.04% surge in the past quarter. The volatility ratio for the week is 6.49%, and the volatility levels for the past 30 days are at 8.51% for LXRX. The simple moving average for the past 20 days is -0.48% for LXRX’s stock, with a 20.77% simple moving average for the past 200 days.
LXRX Trading at 11.86% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.46% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 6.49%, as shares surge +22.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.64% upper at present.
During the last 5 trading sessions, LXRX rose by +0.35%, which changed the moving average for the period of 200-days by +13.28% in comparison to the 20-day moving average, which settled at $2.94. In addition, Lexicon Pharmaceuticals Inc. saw 51.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from Artal International S.C.A., who purchase 16,173,800 shares at the price of $2.50 back on Aug 01. After this action, Artal International S.C.A. now owns 48,433,261 shares of Lexicon Pharmaceuticals Inc., valued at $40,434,500 using the latest closing price.
Invus US Partners LLC, the Director of Lexicon Pharmaceuticals Inc., purchase 982,600 shares at $2.50 during a trade that took place back on Aug 01, which means that Invus US Partners LLC is holding 5,303,814 shares at $2,456,500 based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -72489.21 for the present operating margin
- -207.19 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc. stands at -73341.01. The total capital return value is set at -69.90, while invested capital returns managed to touch -71.31. Equity return is now at value -105.10, with -66.80 for asset returns.
Based on Lexicon Pharmaceuticals Inc. (LXRX), the company’s capital structure generated 47.21 points at debt to equity in total, while total debt to capital is 32.07. Total debt to assets is 28.46, with long-term debt to equity ratio resting at 46.11. Finally, the long-term debt to capital ratio is 31.32.
When we switch over and look at the enterprise to sales, we see a ratio of 3,884.24, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 6.62 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.08.
Conclusion
In conclusion, Lexicon Pharmaceuticals Inc. (LXRX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
